- Home
- AQST
as 12-17-2024 4:00pm EST
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | WARREN |
| Market Cap: | 502.6M | IPO Year: | 2018 |
| Target Price: | $10.38 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.44 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.84 - $6.23 | Next Earning Date: | 11-04-2024 |
| Revenue: | $58,900,000 | Revenue Growth: | 22.56% |
| Revenue Growth (this year): | 18.45% | Revenue Growth (next year): | -9.00% |
Stock Insider Trading Activity of Aquestive Therapeutics Inc. (AQST)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Jung Cassie | AQST | Chief Operating Officer | Nov 26 '24 | Sell | $4.87 | 44 | $214.06 | 0 |
Latest Aquestive Therapeutics Inc. News
AQST Breaking Stock News: Dive into AQST Ticker-Specific Updates for Smart Investing
Benzinga
17 hours ago
Developer Of EpiPen Alternative Aquestive Stock Undervalued Despite Strong Clinical Data, Analyst Sees Huge Upside
MT Newswires
a day ago
Cantor Fitzgerald Initiates Aquestive Therapeutics at Overweight With $17 Price Target
Simply Wall St.
a day ago
Aquestive Therapeutics' (NASDAQ:AQST) investors will be pleased with their favorable 88% return over the last year
MT Newswires
16 days ago
Aquestive Therapeutics Receives FDA 'Positive Feedback' for Anaphylm Sublingual Film
GlobeNewswire
16 days ago
Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual Film
Insider Monkey
a month ago
Is Aquestive Therapeutics (AQST) the Best Multibagger Stock to Buy Heading into 2025?
GlobeNewswire
a month ago
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
Simply Wall St.
a month ago
Aquestive Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Compare AQST vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AQST Aquestive Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.